<SEC-DOCUMENT>0001628280-23-015733.txt : 20230504
<SEC-HEADER>0001628280-23-015733.hdr.sgml : 20230504
<ACCEPTANCE-DATETIME>20230504161134
ACCESSION NUMBER:		0001628280-23-015733
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20230504
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20230504
DATE AS OF CHANGE:		20230504

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Lyell Immunopharma, Inc.
		CENTRAL INDEX KEY:			0001806952
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				833006753
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40502
		FILM NUMBER:		23888819

	BUSINESS ADDRESS:	
		STREET 1:		201 HASKINS WAY
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		650 695-0677

	MAIL ADDRESS:	
		STREET 1:		201 HASKINS WAY
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>lyel-20230504.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:dd98a6f3-69a2-43e1-ab68-0cd2f46e8a33,g:1598d9aa-8651-468d-9f65-049b6a7c5f25,d:d311e4e7528d431589fdad3c9825182c--><html xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>lyel-20230504</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i739733f8a8c845f0a2274d21b01731c9_D20230504-20230504" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmQzMTFlNGU3NTI4ZDQzMTU4OWZkYWQzYzk4MjUxODJjL3NlYzpkMzExZTRlNzUyOGQ0MzE1ODlmZGFkM2M5ODI1MTgyY180L2ZyYWc6ZTQ1ODljYmQzNWNiNDAwN2JjNzgyY2E0NmRjM2ZlYmEvdGFibGU6MGVkNmIxZTAzNTVjNDJjZmI0ZTg5ZmJjOWUyYjk1OWQvdGFibGVyYW5nZTowZWQ2YjFlMDM1NWM0MmNmYjRlODlmYmM5ZTJiOTU5ZF8yLTEtMS0xLTc5OTMw_1d2783b1-d1fa-4178-bb43-e4dc33ba1a47">0001806952</ix:nonNumeric><ix:nonNumeric contextRef="i739733f8a8c845f0a2274d21b01731c9_D20230504-20230504" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmQzMTFlNGU3NTI4ZDQzMTU4OWZkYWQzYzk4MjUxODJjL3NlYzpkMzExZTRlNzUyOGQ0MzE1ODlmZGFkM2M5ODI1MTgyY180L2ZyYWc6ZTQ1ODljYmQzNWNiNDAwN2JjNzgyY2E0NmRjM2ZlYmEvdGFibGU6MGVkNmIxZTAzNTVjNDJjZmI0ZTg5ZmJjOWUyYjk1OWQvdGFibGVyYW5nZTowZWQ2YjFlMDM1NWM0MmNmYjRlODlmYmM5ZTJiOTU5ZF8zLTEtMS0xLTc5OTMw_7aa95bdf-357a-41ed-9ac5-b0b6b6fb5d99">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="lyel-20230504.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i739733f8a8c845f0a2274d21b01731c9_D20230504-20230504"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-04</xbrli:startDate><xbrli:endDate>2023-05-04</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="id311e4e7528d431589fdad3c9825182c_1"></div><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">WASHINGTON, D.C. 20549</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________________________________________</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i739733f8a8c845f0a2274d21b01731c9_D20230504-20230504" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmQzMTFlNGU3NTI4ZDQzMTU4OWZkYWQzYzk4MjUxODJjL3NlYzpkMzExZTRlNzUyOGQ0MzE1ODlmZGFkM2M5ODI1MTgyY18xL2ZyYWc6YTQ2MGVlYmI5YjY4NGY4ODgwZDkxODZjNmYxMjI2MWIvdGV4dHJlZ2lvbjphNDYwZWViYjliNjg0Zjg4ODBkOTE4NmM2ZjEyMjYxYl8xNDQ3_b196b367-3410-4afa-920c-31e715ac8f0f">8-K</ix:nonNumeric></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________________________________________</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Date of Report (Date of earliest event reported): <ix:nonNumeric contextRef="i739733f8a8c845f0a2274d21b01731c9_D20230504-20230504" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOmQzMTFlNGU3NTI4ZDQzMTU4OWZkYWQzYzk4MjUxODJjL3NlYzpkMzExZTRlNzUyOGQ0MzE1ODlmZGFkM2M5ODI1MTgyY18xL2ZyYWc6YTQ2MGVlYmI5YjY4NGY4ODgwZDkxODZjNmYxMjI2MWIvdGV4dHJlZ2lvbjphNDYwZWViYjliNjg0Zjg4ODBkOTE4NmM2ZjEyMjYxYl81NDk3NTU4MTUzNDE_9b27b38e-7b0e-4476-8ff6-de99988337b9">May&#160;4, 2023</ix:nonNumeric></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________________________________________</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i739733f8a8c845f0a2274d21b01731c9_D20230504-20230504" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmQzMTFlNGU3NTI4ZDQzMTU4OWZkYWQzYzk4MjUxODJjL3NlYzpkMzExZTRlNzUyOGQ0MzE1ODlmZGFkM2M5ODI1MTgyY18xL2ZyYWc6YTQ2MGVlYmI5YjY4NGY4ODgwZDkxODZjNmYxMjI2MWIvdGV4dHJlZ2lvbjphNDYwZWViYjliNjg0Zjg4ODBkOTE4NmM2ZjEyMjYxYl8xNDQ5_16808414-3cad-4d72-b43d-bf0e7f66546a">Lyell Immunopharma, Inc.</ix:nonNumeric></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(Exact name of Registrant as Specified in Its Charter)</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________________________________________</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.203%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.204%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i739733f8a8c845f0a2274d21b01731c9_D20230504-20230504" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmQzMTFlNGU3NTI4ZDQzMTU4OWZkYWQzYzk4MjUxODJjL3NlYzpkMzExZTRlNzUyOGQ0MzE1ODlmZGFkM2M5ODI1MTgyY18xL2ZyYWc6YTQ2MGVlYmI5YjY4NGY4ODgwZDkxODZjNmYxMjI2MWIvdGFibGU6OThkZWJmM2FlOTMzNDA4MjkxOTUzNDBjYWMwMjg1MzAvdGFibGVyYW5nZTo5OGRlYmYzYWU5MzM0MDgyOTE5NTM0MGNhYzAyODUzMF8wLTAtMS0xLTc5OTMw_f5b740b9-a54c-4b88-ac6a-d716b03ef50b">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i739733f8a8c845f0a2274d21b01731c9_D20230504-20230504" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmQzMTFlNGU3NTI4ZDQzMTU4OWZkYWQzYzk4MjUxODJjL3NlYzpkMzExZTRlNzUyOGQ0MzE1ODlmZGFkM2M5ODI1MTgyY18xL2ZyYWc6YTQ2MGVlYmI5YjY4NGY4ODgwZDkxODZjNmYxMjI2MWIvdGFibGU6OThkZWJmM2FlOTMzNDA4MjkxOTUzNDBjYWMwMjg1MzAvdGFibGVyYW5nZTo5OGRlYmYzYWU5MzM0MDgyOTE5NTM0MGNhYzAyODUzMF8wLTItMS0xLTc5OTMw_0ec8395b-1539-49c9-9719-d7a5e32380a8">001-40502</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i739733f8a8c845f0a2274d21b01731c9_D20230504-20230504" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmQzMTFlNGU3NTI4ZDQzMTU4OWZkYWQzYzk4MjUxODJjL3NlYzpkMzExZTRlNzUyOGQ0MzE1ODlmZGFkM2M5ODI1MTgyY18xL2ZyYWc6YTQ2MGVlYmI5YjY4NGY4ODgwZDkxODZjNmYxMjI2MWIvdGFibGU6OThkZWJmM2FlOTMzNDA4MjkxOTUzNDBjYWMwMjg1MzAvdGFibGVyYW5nZTo5OGRlYmYzYWU5MzM0MDgyOTE5NTM0MGNhYzAyODUzMF8wLTQtMS0xLTc5OTMw_466789f5-4b1d-448e-a11e-6e1fafb8376d">83-1300510</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(State or Other Jurisdiction <br/>of Incorporation)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(Commission File Number)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(IRS Employer <br/>Identification No.)</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i739733f8a8c845f0a2274d21b01731c9_D20230504-20230504" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmQzMTFlNGU3NTI4ZDQzMTU4OWZkYWQzYzk4MjUxODJjL3NlYzpkMzExZTRlNzUyOGQ0MzE1ODlmZGFkM2M5ODI1MTgyY18xL2ZyYWc6YTQ2MGVlYmI5YjY4NGY4ODgwZDkxODZjNmYxMjI2MWIvdGFibGU6OThkZWJmM2FlOTMzNDA4MjkxOTUzNDBjYWMwMjg1MzAvdGFibGVyYW5nZTo5OGRlYmYzYWU5MzM0MDgyOTE5NTM0MGNhYzAyODUzMF8zLTAtMS0xLTc5OTMw_b35d179e-8f6d-446c-8d21-d4141511617f">201 Haskins Way</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i739733f8a8c845f0a2274d21b01731c9_D20230504-20230504" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmQzMTFlNGU3NTI4ZDQzMTU4OWZkYWQzYzk4MjUxODJjL3NlYzpkMzExZTRlNzUyOGQ0MzE1ODlmZGFkM2M5ODI1MTgyY18xL2ZyYWc6YTQ2MGVlYmI5YjY4NGY4ODgwZDkxODZjNmYxMjI2MWIvdGFibGU6OThkZWJmM2FlOTMzNDA4MjkxOTUzNDBjYWMwMjg1MzAvdGFibGVyYW5nZTo5OGRlYmYzYWU5MzM0MDgyOTE5NTM0MGNhYzAyODUzMF80LTAtMS0xLTc5OTMwL3RleHRyZWdpb246ZjUzMDM5ZWEwOTE1NGMwZjg5NzZmOTUzNWI0ODBlN2NfNA_abf802e4-5f7a-4d97-8fa2-36746c301339">South San Francisco</ix:nonNumeric>, <ix:nonNumeric contextRef="i739733f8a8c845f0a2274d21b01731c9_D20230504-20230504" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmQzMTFlNGU3NTI4ZDQzMTU4OWZkYWQzYzk4MjUxODJjL3NlYzpkMzExZTRlNzUyOGQ0MzE1ODlmZGFkM2M5ODI1MTgyY18xL2ZyYWc6YTQ2MGVlYmI5YjY4NGY4ODgwZDkxODZjNmYxMjI2MWIvdGFibGU6OThkZWJmM2FlOTMzNDA4MjkxOTUzNDBjYWMwMjg1MzAvdGFibGVyYW5nZTo5OGRlYmYzYWU5MzM0MDgyOTE5NTM0MGNhYzAyODUzMF80LTAtMS0xLTc5OTMwL3RleHRyZWdpb246ZjUzMDM5ZWEwOTE1NGMwZjg5NzZmOTUzNWI0ODBlN2NfOA_1c0041af-e184-45ef-9f1d-d3899ba82393">California</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i739733f8a8c845f0a2274d21b01731c9_D20230504-20230504" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmQzMTFlNGU3NTI4ZDQzMTU4OWZkYWQzYzk4MjUxODJjL3NlYzpkMzExZTRlNzUyOGQ0MzE1ODlmZGFkM2M5ODI1MTgyY18xL2ZyYWc6YTQ2MGVlYmI5YjY4NGY4ODgwZDkxODZjNmYxMjI2MWIvdGFibGU6OThkZWJmM2FlOTMzNDA4MjkxOTUzNDBjYWMwMjg1MzAvdGFibGVyYW5nZTo5OGRlYmYzYWU5MzM0MDgyOTE5NTM0MGNhYzAyODUzMF80LTQtMS0xLTc5OTMw_54e6ec83-baa3-4490-bf14-d1b7bf569c23">94080</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(Address of Principal Executive Offices)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(Zip Code)</span></td></tr></table></div><div style="margin-top:3pt;padding-left:1.05pt;padding-right:1.05pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Registrant&#8217;s Telephone Number, Including Area Code:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i739733f8a8c845f0a2274d21b01731c9_D20230504-20230504" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmQzMTFlNGU3NTI4ZDQzMTU4OWZkYWQzYzk4MjUxODJjL3NlYzpkMzExZTRlNzUyOGQ0MzE1ODlmZGFkM2M5ODI1MTgyY18xL2ZyYWc6YTQ2MGVlYmI5YjY4NGY4ODgwZDkxODZjNmYxMjI2MWIvdGV4dHJlZ2lvbjphNDYwZWViYjliNjg0Zjg4ODBkOTE4NmM2ZjEyMjYxYl8xNDUw_7ffd3a77-4bca-405b-a54d-3b48e0c9f219">650</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i739733f8a8c845f0a2274d21b01731c9_D20230504-20230504" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmQzMTFlNGU3NTI4ZDQzMTU4OWZkYWQzYzk4MjUxODJjL3NlYzpkMzExZTRlNzUyOGQ0MzE1ODlmZGFkM2M5ODI1MTgyY18xL2ZyYWc6YTQ2MGVlYmI5YjY4NGY4ODgwZDkxODZjNmYxMjI2MWIvdGV4dHJlZ2lvbjphNDYwZWViYjliNjg0Zjg4ODBkOTE4NmM2ZjEyMjYxYl8xNDQ0_d6d4be8d-409d-4f53-a98f-8411443baf74">695-0677</ix:nonNumeric></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Former Name or Former Address, if Changed Since Last Report)</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Not Applicable</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________________________________________</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.810%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonNumeric contextRef="i739733f8a8c845f0a2274d21b01731c9_D20230504-20230504" name="dei:WrittenCommunications" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmQzMTFlNGU3NTI4ZDQzMTU4OWZkYWQzYzk4MjUxODJjL3NlYzpkMzExZTRlNzUyOGQ0MzE1ODlmZGFkM2M5ODI1MTgyY18xL2ZyYWc6YTQ2MGVlYmI5YjY4NGY4ODgwZDkxODZjNmYxMjI2MWIvdGFibGU6NGQxMjU4OTU1Y2JiNDM3ZDg1ZWU2ZDE2ZGVjOThiY2MvdGFibGVyYW5nZTo0ZDEyNTg5NTVjYmI0MzdkODVlZTZkMTZkZWM5OGJjY18wLTAtMS0xLTc5OTMw_9e28390f-decb-46f4-8936-8727ad92aace">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonNumeric contextRef="i739733f8a8c845f0a2274d21b01731c9_D20230504-20230504" name="dei:SolicitingMaterial" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmQzMTFlNGU3NTI4ZDQzMTU4OWZkYWQzYzk4MjUxODJjL3NlYzpkMzExZTRlNzUyOGQ0MzE1ODlmZGFkM2M5ODI1MTgyY18xL2ZyYWc6YTQ2MGVlYmI5YjY4NGY4ODgwZDkxODZjNmYxMjI2MWIvdGFibGU6NGQxMjU4OTU1Y2JiNDM3ZDg1ZWU2ZDE2ZGVjOThiY2MvdGFibGVyYW5nZTo0ZDEyNTg5NTVjYmI0MzdkODVlZTZkMTZkZWM5OGJjY18yLTAtMS0xLTc5OTMw_ea56a240-bfff-4b74-88c7-d2cbeb286d98">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonNumeric contextRef="i739733f8a8c845f0a2274d21b01731c9_D20230504-20230504" name="dei:PreCommencementTenderOffer" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmQzMTFlNGU3NTI4ZDQzMTU4OWZkYWQzYzk4MjUxODJjL3NlYzpkMzExZTRlNzUyOGQ0MzE1ODlmZGFkM2M5ODI1MTgyY18xL2ZyYWc6YTQ2MGVlYmI5YjY4NGY4ODgwZDkxODZjNmYxMjI2MWIvdGFibGU6NGQxMjU4OTU1Y2JiNDM3ZDg1ZWU2ZDE2ZGVjOThiY2MvdGFibGVyYW5nZTo0ZDEyNTg5NTVjYmI0MzdkODVlZTZkMTZkZWM5OGJjY180LTAtMS0xLTc5OTMw_252e8134-2de0-45ca-b010-ce2ffa9e3935">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonNumeric contextRef="i739733f8a8c845f0a2274d21b01731c9_D20230504-20230504" name="dei:PreCommencementIssuerTenderOffer" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmQzMTFlNGU3NTI4ZDQzMTU4OWZkYWQzYzk4MjUxODJjL3NlYzpkMzExZTRlNzUyOGQ0MzE1ODlmZGFkM2M5ODI1MTgyY18xL2ZyYWc6YTQ2MGVlYmI5YjY4NGY4ODgwZDkxODZjNmYxMjI2MWIvdGFibGU6NGQxMjU4OTU1Y2JiNDM3ZDg1ZWU2ZDE2ZGVjOThiY2MvdGFibGVyYW5nZTo0ZDEyNTg5NTVjYmI0MzdkODVlZTZkMTZkZWM5OGJjY182LTAtMS0xLTc5OTMw_2a434894-8cc9-4ee3-ac7c-200e31fe1366">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></div></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.142%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.295%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading<br/>Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i739733f8a8c845f0a2274d21b01731c9_D20230504-20230504" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmQzMTFlNGU3NTI4ZDQzMTU4OWZkYWQzYzk4MjUxODJjL3NlYzpkMzExZTRlNzUyOGQ0MzE1ODlmZGFkM2M5ODI1MTgyY18xL2ZyYWc6YTQ2MGVlYmI5YjY4NGY4ODgwZDkxODZjNmYxMjI2MWIvdGFibGU6YThlNTU4OGE1ZGJiNGIyYzlmMTEwNDljODMzZWZmYjUvdGFibGVyYW5nZTphOGU1NTg4YTVkYmI0YjJjOWYxMTA0OWM4MzNlZmZiNV8xLTAtMS0xLTc5OTMw_e084dac1-37fc-43ef-b791-2b1bcecd3a5c">Common Stock, $0.0001 par value per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i739733f8a8c845f0a2274d21b01731c9_D20230504-20230504" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmQzMTFlNGU3NTI4ZDQzMTU4OWZkYWQzYzk4MjUxODJjL3NlYzpkMzExZTRlNzUyOGQ0MzE1ODlmZGFkM2M5ODI1MTgyY18xL2ZyYWc6YTQ2MGVlYmI5YjY4NGY4ODgwZDkxODZjNmYxMjI2MWIvdGFibGU6YThlNTU4OGE1ZGJiNGIyYzlmMTEwNDljODMzZWZmYjUvdGFibGVyYW5nZTphOGU1NTg4YTVkYmI0YjJjOWYxMTA0OWM4MzNlZmZiNV8xLTItMS0xLTc5OTMw_834355cc-580c-49fd-93ba-0e696572e6ae">LYEL</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i739733f8a8c845f0a2274d21b01731c9_D20230504-20230504" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmQzMTFlNGU3NTI4ZDQzMTU4OWZkYWQzYzk4MjUxODJjL3NlYzpkMzExZTRlNzUyOGQ0MzE1ODlmZGFkM2M5ODI1MTgyY18xL2ZyYWc6YTQ2MGVlYmI5YjY4NGY4ODgwZDkxODZjNmYxMjI2MWIvdGFibGU6YThlNTU4OGE1ZGJiNGIyYzlmMTEwNDljODMzZWZmYjUvdGFibGVyYW5nZTphOGU1NTg4YTVkYmI0YjJjOWYxMTA0OWM4MzNlZmZiNV8xLTQtMS0xLTc5OTMw_72514af5-1baf-4b4a-b2a1-65536da595a9">NASDAQ Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#8239;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#8239;240.12b-2 of this chapter). </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i739733f8a8c845f0a2274d21b01731c9_D20230504-20230504" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmQzMTFlNGU3NTI4ZDQzMTU4OWZkYWQzYzk4MjUxODJjL3NlYzpkMzExZTRlNzUyOGQ0MzE1ODlmZGFkM2M5ODI1MTgyY18xL2ZyYWc6YTQ2MGVlYmI5YjY4NGY4ODgwZDkxODZjNmYxMjI2MWIvdGV4dHJlZ2lvbjphNDYwZWViYjliNjg0Zjg4ODBkOTE4NmM2ZjEyMjYxYl8xNDQ1_af72d6f6-909a-45f3-83a4-8420385e49fb">o</ix:nonNumeric></span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="id311e4e7528d431589fdad3c9825182c_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.02 Results of Operations and Financial Condition.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May&#160;4, 2023, Lyell Immunopharma, Inc. (the &#8220;Company&#8221;) issued a press release announcing its financial results for the quarter ended March&#160;31, 2023. A copy of the press release is attached hereto as Exhibit&#160;99.1.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information in this Item&#160;2.02, including the attached Exhibit&#160;99.1, is being furnished and shall not be deemed &#8220;filed&#8221; for the purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.</span></div><div id="id311e4e7528d431589fdad3c9825182c_10"></div><div style="-sec-extract:summary;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01 Financial Statements and Exhibits.</span></div><div style="margin-top:12pt"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d) Exhibits</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.203%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:72.991%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Description</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lyel-20230504x8kexx991.htm">Press Release Dated May 4, 2023</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="id311e4e7528d431589fdad3c9825182c_13"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.021%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.324%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.355%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lyell Immunopharma, Inc.</span></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">May 4, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ CHARLES NEWTON</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Charles Newton</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Financial Officer</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>lyel-20230504x8kexx991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="id105ff2232d14b94bdf6b6df5498c9c9_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="text-align:right;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div><div style="text-align:justify"><img alt="a0000a.jpg" src="a0000a.jpg" style="height:84px;margin-bottom:5pt;vertical-align:text-bottom;width:120px"></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2023</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Two phase 1 clinical trials recruiting patients at 14 sites across the US&#59; nine sites for LYL797, a ROR-1-targeted chimeric antigen receptor T cell (CAR-T) product candidate, and five sites for LYL845, a tumor infiltrating lymphocyte (TIL) product candidate </font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Cash, cash equivalents and marketable securities of $668.0&#160;million as of March&#160;31, 2023 support advancing robust pipeline into 2026, through multiple clinical milestones</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SOUTH SAN FRANCISCO, Calif., May 4, 2023 -- Lyell Immunopharma, Inc. (Nasdaq&#58; LYEL), a clinical&#8209;stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors today reported financial results and business highlights for the first quarter ended March&#160;31, 2023.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;We remain focused on accumulating data in the two Phase 1 clinical trials of our wholly owned CAR T cell and TIL product candidates,&#8221; said Lynn Seely, M.D., Lyell&#8217;s President and CEO. &#8220;With more than a dozen sites now open and actively screening and enrolling patients across these two trials, I am pleased with the progress we are making. We are paving the way for two initial clinical data readouts in 2024 that we expect will provide important insights on the potential of our T cell reprogramming technologies to benefit patients with solid tumors. Our strong financial position with cash runway into 2026 positions us to focus on execution, while also advancing new technologies being deployed in our pipeline of novel product candidates.&#8221;</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">First Quarter Updates and Recent Business Highlights</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lyell is advancing four wholly-owned product candidates&#58; two product candidates, LYL797 and LYL845, are in Phase 1 clinical development and two additional product candidates, LYL119 and a TIL product candidate incorporating novel genetic and epigenetic reprogramming technologies, are in preclinical development. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">LYL797 &#8211; A ROR1 CAR T-cell product candidate genetically reprogrammed using c-Jun and epigenetically reprogrammed using Lyell&#8217;s proprietary Epi-R</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> manufacturing protocol, designed for differentiated potency and durability</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Enrollment in the Phase 1 clinical trial of LYL797 is ongoing at nine sites in the US. The study is enrolling patients with relapsed or refractory triple-negative breast cancer or non-small cell lung cancer. Initial clinical data from the Phase 1 trial of LYL797 are expected in the first half of 2024.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">LYL845 &#8211; A novel epigenetically reprogrammed TIL product candidate designed for differentiated potency and durability</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Enrollment in the Phase 1 clinical trial for LYL845 is ongoing at five sites in the US. The study is enrolling patients with relapsed and&#47;or refractory metastatic or locally advanced melanoma, non-small cell lung cancer and colorectal cancer. Initial clinical data from the Phase 1 trial of LYL845 are expected in 2024.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">LYL119 &#8211; An innovative ROR1 CAR T-cell product designed for enhanced cytotoxicity </font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">An IND for LYL119 is expected to be submitted in the first half of 2024.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">An abstract highlighting preclinical development of LYL119 has been selected for presentation at the American Society for Gene and Cell Therapy (ASGCT) 26</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Annual Meeting taking place in Los Angeles, CA May 16-20, 2023.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">First Quarter Financial Results</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lyell reported a net loss of $67.0 million for the </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">first</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> quarter ended March&#160;31, 2023, compared to a net loss of $68.1 million for the same period in 2022. Non&#8209;GAAP net loss, which excludes non-cash stock-based compensation, non&#8209;cash expenses related to the change in the estimated fair value of success payment liabilities and certain non-cash investment </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">gains and charges, was $44.8&#160;million for the </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">first</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> quarter ended March&#160;31, 2023, compared to $50.0 million for the same period in 2022.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Revenue was $0.1 million for the </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">first</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> quarter ended March&#160;31, 2023 compared to $0.6 million for the same period in 2022. No research and development pursuant to our collaboration and license agreement with </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GlaxoSmithKline</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (GSK Agreement) was performed in the first quarter of 2023 due to the termination of the GSK Agreement in December 2022, which drove the $0.5&#160;million decrease in revenue.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">GAAP and Non-GAAP Operating Expenses</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Research and development (R&#38;D) expenses were $44.6 million for the first quarter ended March&#160;31, 2023, compared to $35.8 million for the same period in 2022. The increase in first quarter 2023 R&#38;D expenses was primarily driven by non-cash expenses related to the change in the estimated fair value of success payment liabilities and an increase in personnel-related expenses, primarily related to an increase in headcount to expand our R&#38;D and manufacturing capabilities. Non&#8209;GAAP R&#38;D expenses, which exclude non-cash stock-based compensation and non-cash expenses related to the change in the estimated fair value of success payment liabilities for the first quarter ended March&#160;31, 2023, were $40.6&#160;million compared to $35.9&#160;million for the same period in 2022. The increase in first quarter 2023 non-GAAP R&#38;D expenses was driven by increased personnel-related expenses, primarily related to an increase in headcount to expand our clinical development and manufacturing capabilities in support of our ongoing clinical trials. </font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">General and administrative (G&#38;A) expenses were $19.3 million for the first quarter ended March&#160;31, 2023, compared to $34.4 million for the same period in 2022. The decrease in first quarter 2023 G&#38;A expenses was primarily driven by changes in non-cash stock-based compensation. Non&#8209;GAAP G&#38;A expenses, which exclude non-cash stock-based compensation, for the first quarter ended March&#160;31, 2023, were $10.0&#160;million, compared to $16.2&#160;million for the same period in 2022. The decrease in first quarter 2023 non-GAAP G&#38;A expenses was driven by a decrease in legal expenses.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A discussion of non-GAAP financial measures, including reconciliations of the most comparable GAAP measures to non&#8209;GAAP financial measures, is presented below under &#8220;Non-GAAP Financial Measures.&#8221;</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash, cash equivalents and marketable securities</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents and marketable securities as of March&#160;31, 2023 were $668.0 million, compared to $710.3 million as of December&#160;31, 2022. Lyell believes that its cash, cash equivalents and marketable securities balances will be sufficient to meet working capital and capital expenditure needs into 2026.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">About Lyell Immunopharma, Inc.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lyell is a</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> clinical-stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors. The technologies powering its product candidates are </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">designed to address barriers that limit consistent and long-lasting responses to cell therapy for solid tumors&#58; T-cell exhaustion and lack of durable stemness, which includes the ability to persist and self-renew to drive durable tumor cytotoxicity. Lyell is applying its proprietary </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ex vivo</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> genetic and epigenetic reprogramming technologies to address these barriers in order to develop new medicines with improved durable clinical outcomes. Lyell is based in South San Francisco, California with facilities in Seattle and Bothell, Washington. To learn more, please visit www.lyell.com. </font></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Forward-Looking Statements</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements expressed or implied in this press release include, but are not limited to, statements regarding&#58; Lyell&#8217;s anticipated progress, business plans, business strategy and clinical trials&#59; Lyell advancement of its pipeline or its capabilities&#59; the potential clinical benefits and therapeutic potential of Lyell&#8217;s product candidates&#59; Lyell&#8217;s expectation that its strong financial position with cash runway into 2026 will support advancement of its pipeline&#59; Lyell&#8217;s plans to submit an IND for LYL119 and the timing thereof&#59; expectations around patient profiles, enrollment and timing of initial clinical data from Lyell&#8217;s Phase 1 trials for LYL797 and LYL845&#59; and other statements that are</font><font style="color:#333f48;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">not historical fact. These statements are based on Lyell&#8217;s current plans, objectives, estimates, expectations and intentions, are not guarantees of future performance and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, but are not limited to, risks and uncertainties related to&#58; the effects of geopolitical instability&#59; macroeconomic conditions and the COVID-19 pandemic&#59; Lyell&#8217;s ability to submit planned INDs or initiate or progress clinical trials on the anticipated timelines, if at all&#59; Lyell&#8217;s limited experience as a company in enrolling and conducting clinical trials, and lack of experience in completing clinical trials&#59; Lyell&#8217;s ability to manufacture and supply its product candidates for its clinical trials&#59; the nonclinical profiles of Lyell&#8217;s product candidates not translating in clinical trials&#59; the potential for results from clinical trials to differ from nonclinical, early clinical, preliminary or expected results&#59; significant adverse events, toxicities or other undesirable side effects associated with Lyell&#8217;s product candidates&#59; the significant uncertainty associated with Lyell&#8217;s product candidates ever receiving any regulatory approvals&#59; Lyell&#8217;s ability to obtain, maintain or protect intellectual property rights related to its product candidates&#59; implementation of Lyell&#8217;s strategic plans for its business and product candidates&#59; the sufficiency of Lyell&#8217;s capital resources and need for additional capital to achieve its goals&#59; and other risks, including those described under the heading &#8220;Risk Factors&#8221; in its Annual Report on Form 10-K for the year ended December&#160;31, 2022, filed with the Securities and Exchange Commission (SEC) on February 28, 2023, and the Quarterly Report on Form 10-Q for the quarter ended March&#160;31, 2023, being filed with the SEC today. Forward-looking statements contained in this press release are made as of this date, and Lyell undertakes no duty to update such information except as required under applicable law.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="id105ff2232d14b94bdf6b6df5498c9c9_4"></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lyell Immunopharma, Inc.</font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Unaudited Selected Consolidated Financial Data</font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands)</font></div><div style="margin-top:6pt;text-align:center"><font><br></font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Statement of Operations Data&#58;</font></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"></td><td style="width:65.516%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.288%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.290%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">65&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">553&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:14.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">44,630&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">35,830&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 15.4pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">19,279&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">34,421&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 15.4pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating income, net</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(1,288)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(1,122)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</font></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">62,621&#160;</font></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">69,129&#160;</font></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</font></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(62,556)</font></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(68,576)</font></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 15.4pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income, net</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">4,497&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">397&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:14.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">1,100&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">35&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 15.4pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of other investments</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(10,000)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other (loss) income, net</font></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(4,403)</font></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">432&#160;</font></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(66,959)</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(68,144)</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:26.68pt">As of December 31, 2022, the Company&#8217;s success payment liability was recognized at fair value as Fred Hutchinson Cancer Center (Fred Hutch) had provided the requisite service obligation to earn the potential success payment consideration under the continued collaboration. The change in the estimated fair value of Fred Hutch success payment liabilities beginning in Q1 2023 was recognized within other income, net in the unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss. The change in the estimated fair value of Fred Hutch success payment liabilities for Q1 2022 was recognized within research and development expenses in the unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss. </font></div><div style="margin-top:6pt;text-align:center"><font><br></font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance Sheet Data&#58;</font></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.203%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.355%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of March 31, 2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2022</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and marketable securities</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">668,024&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">710,269&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118,600&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123,023&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">880,450&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">937,561&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">783,826&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">833,252&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="id105ff2232d14b94bdf6b6df5498c9c9_10"></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-GAAP Financial Measures</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To supplement our financial results and guidance presented in accordance with U.S. generally accepted accounting principles (GAAP), we present non-GAAP net loss, non-GAAP R&#38;D expenses and non-GAAP G&#38;A expenses. Non&#8209;GAAP net loss and non-GAAP R&#38;D expenses exclude non-cash stock-based compensation expense and non-cash expenses related to the change in the estimated fair value of success payment liabilities from GAAP net loss and GAAP R&#38;D expenses. As of December&#160;31, 2022, our Fred Hutch success payment liability was recognized at fair value as Fred Hutch had provided the requisite service obligation to earn the potential success payment consideration under the continued collaboration. For the three months ended March&#160;31, 2023 and future periods, the change in the Fred Hutch success payment liability fair value is recognized in other income, net, as the requisite service obligation had been met, whereas it was previously recognized within research and development expenses. Non-GAAP net loss further adjusts non-cash investment gains and charges, as applicable, and for the income tax effect, if any, of the non-GAAP adjustments. Non&#8209;GAAP G&#38;A expenses exclude non-cash stock-based compensation expense from GAAP G&#38;A expenses. We believe that these non-GAAP financial measures, when considered together with our financial information prepared in accordance with GAAP, can enhance investors&#8217; and analysts&#8217; ability to meaningfully compare our results from period to period, and to identify operating trends in our business. We have excluded stock-based compensation expense, non-cash expenses related to the change in the estimated fair value of success payment liabilities and non-cash investment gains and charges from our non-GAAP financial measures because they are non-cash gains and charges that may vary significantly from period to period as a result of changes not directly or immediately related to the operational performance for the periods presented. We also regularly use these non-GAAP financial measures internally to understand, manage and evaluate our business and to make operating decisions. These non-GAAP financial measures are in addition to, and not a substitute for or superior to, measures of financial performance prepared in accordance with GAAP. In addition, these non-GAAP financial measures have no standardized meaning prescribed by GAAP and are not prepared under any comprehensive set of accounting rules or principles and, therefore, have limits in their usefulness to investors. We encourage investors to carefully consider our results under GAAP, as well as our supplemental non-GAAP financial information, to more fully understand our business.</font></div><div id="id105ff2232d14b94bdf6b6df5498c9c9_13"></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lyell Immunopharma, Inc.</font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Unaudited Reconciliation of GAAP to Non-GAAP Net Loss</font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands)</font></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.293%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.901%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss - GAAP</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66,959)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68,144)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,882&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,028&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in the estimated fair value of success payment liabilities</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,708)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,851)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of other investments</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,000&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss - Non-GAAP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</font></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44,785)</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49,967)</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:26.68pt">There was no income tax effect related to the adjustments made to calculate non-GAAP net loss because of the full valuation allowance on our net U.S. deferred tax assets for all periods presented. </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="id105ff2232d14b94bdf6b6df5498c9c9_16"></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lyell Immunopharma, Inc.</font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Unaudited Reconciliation of GAAP to Non-GAAP Research and Development Expenses</font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands)</font></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.293%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.901%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense - GAAP</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,630&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,830&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,612)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,764)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in the estimated fair value of success payment liabilities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">608&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,851&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense - Non-GAAP</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,626&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,917&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:26.68pt">As of December 31, 2022, the Company&#8217;s success payment liability was recognized at fair value as Fred Hutch had provided the requisite service obligation to earn the potential success payment consideration under the continued collaboration.  The change in the estimated fair value of Fred Hutch success payment liabilities beginning in Q1 2023 was recognized within other income, net in the unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss. The change in the estimated fair value of Fred Hutch success payment liabilities for Q1 2022 was recognized within research and development expenses in the unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss. </font></div><div id="id105ff2232d14b94bdf6b6df5498c9c9_19"></div><div style="text-align:center"><font><br></font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lyell Immunopharma, Inc.</font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Unaudited Reconciliation of GAAP to Non-GAAP General and Administrative Expenses</font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands)</font></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.293%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.901%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expense - GAAP</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,279&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,421&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,270)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,264)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expense - Non-GAAP</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,009&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,157&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:18pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contact&#58;</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ellen Rose</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Senior Vice President, Communications and Investor Relations</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">erose&#64;lyell.com</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>lyel-20230504.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:dd98a6f3-69a2-43e1-ab68-0cd2f46e8a33,g:1598d9aa-8651-468d-9f65-049b6a7c5f25-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:lyel="http://www.lyell.com/20230504" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.lyell.com/20230504">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lyel-20230504_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lyel-20230504_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.lyell.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>lyel-20230504_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:dd98a6f3-69a2-43e1-ab68-0cd2f46e8a33,g:1598d9aa-8651-468d-9f65-049b6a7c5f25-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_EntityTaxIdentificationNumber_aa6207ce-4489-4013-b842-fb562e207955_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_77850121-1698-48a1-98ad-d8e11c9329ba_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_9cac0e6c-1fb6-4c3e-9d4e-1b072069b039_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_2de9cc92-b22e-4ce0-93fe-e6c374f18294_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_fe22427c-ebfb-424c-851e-58a22f23ad1a_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_a4e46b82-1c25-42a6-9b46-6416f9a71b91_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_87d6e170-ebb2-4593-a1e0-1536d9b77921_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_19578dc2-7bbf-47de-8583-cd626e29680d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_78e42403-2e93-4788-8bbb-6dbaaafa4fdc_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_f48e9f31-fedf-4855-961d-fcab657fb3d9_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_82183877-1cfb-41dc-aec7-1162eb2bb3e8_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_0e96e148-1e18-454a-9769-bda80bf9f9cd_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_f2aa180a-c964-48b1-900c-ce17cd775cda_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_a9e6351f-2e3a-4ab9-a917-365d3716a2dc_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_66b3e400-f9b3-402e-ac13-42730812e7b4_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_535e56ed-1254-498a-82e0-c133dc3b0f31_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_a8e1f99c-17f3-41d9-bf60-e333adbb31bf_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_86cac13c-7c27-4998-9665-93ad7b319429_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_dacc32d9-a7ce-4652-8e1b-f4188e81b5b1_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_a5694593-1cc2-4a84-92c3-709f6a72a701_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_a66e0ab3-383c-4470-bbfe-e83c55ec34eb_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_126bd942-5349-4141-bef2-48ffd2558c64_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>lyel-20230504_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:dd98a6f3-69a2-43e1-ab68-0cd2f46e8a33,g:1598d9aa-8651-468d-9f65-049b6a7c5f25-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.lyell.com/role/Cover" xlink:type="simple" xlink:href="lyel-20230504.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.lyell.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_b81d40f5-96c1-489c-981e-864f0cc801c2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_b825e5ad-c984-4e79-8224-f0899a8fab54" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b81d40f5-96c1-489c-981e-864f0cc801c2" xlink:to="loc_dei_EntityCentralIndexKey_b825e5ad-c984-4e79-8224-f0899a8fab54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_b850ac39-edc1-48d4-aed8-72ae024a2407" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b81d40f5-96c1-489c-981e-864f0cc801c2" xlink:to="loc_dei_AmendmentFlag_b850ac39-edc1-48d4-aed8-72ae024a2407" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_1b3b1f37-6356-4e04-bce9-955d27f9d0e1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b81d40f5-96c1-489c-981e-864f0cc801c2" xlink:to="loc_dei_DocumentPeriodEndDate_1b3b1f37-6356-4e04-bce9-955d27f9d0e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_5a5c5aff-b7fc-4d2f-866d-df773725075c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b81d40f5-96c1-489c-981e-864f0cc801c2" xlink:to="loc_dei_DocumentType_5a5c5aff-b7fc-4d2f-866d-df773725075c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_914d43b2-c64a-44e6-a03a-0fbdcac28be3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b81d40f5-96c1-489c-981e-864f0cc801c2" xlink:to="loc_dei_EntityRegistrantName_914d43b2-c64a-44e6-a03a-0fbdcac28be3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_efce0786-e265-4204-b172-3b499e64c9af" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b81d40f5-96c1-489c-981e-864f0cc801c2" xlink:to="loc_dei_EntityIncorporationStateCountryCode_efce0786-e265-4204-b172-3b499e64c9af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_f2bd2738-f541-433f-ac96-e23488b03886" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b81d40f5-96c1-489c-981e-864f0cc801c2" xlink:to="loc_dei_EntityFileNumber_f2bd2738-f541-433f-ac96-e23488b03886" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_68053bce-3a57-482c-b62e-3e8f286c25fc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b81d40f5-96c1-489c-981e-864f0cc801c2" xlink:to="loc_dei_EntityTaxIdentificationNumber_68053bce-3a57-482c-b62e-3e8f286c25fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_d2e3c72c-9085-4f25-853d-9b9d8023ccf4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b81d40f5-96c1-489c-981e-864f0cc801c2" xlink:to="loc_dei_EntityAddressAddressLine1_d2e3c72c-9085-4f25-853d-9b9d8023ccf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_663afbfc-e93f-4102-af02-a913db949ad2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b81d40f5-96c1-489c-981e-864f0cc801c2" xlink:to="loc_dei_EntityAddressCityOrTown_663afbfc-e93f-4102-af02-a913db949ad2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_42a10ed7-d6ec-4a42-bcdd-8ac08bd93ee3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b81d40f5-96c1-489c-981e-864f0cc801c2" xlink:to="loc_dei_EntityAddressStateOrProvince_42a10ed7-d6ec-4a42-bcdd-8ac08bd93ee3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_58d420b6-e7be-46bf-87d9-c921cae817de" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b81d40f5-96c1-489c-981e-864f0cc801c2" xlink:to="loc_dei_EntityAddressPostalZipCode_58d420b6-e7be-46bf-87d9-c921cae817de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_d4b1e767-6138-4849-92f3-e50c3d515fff" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b81d40f5-96c1-489c-981e-864f0cc801c2" xlink:to="loc_dei_CityAreaCode_d4b1e767-6138-4849-92f3-e50c3d515fff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_6354e1c6-063d-4004-8c00-6bd2f928c4c4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b81d40f5-96c1-489c-981e-864f0cc801c2" xlink:to="loc_dei_LocalPhoneNumber_6354e1c6-063d-4004-8c00-6bd2f928c4c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_2da1ce09-d23e-4f80-ba0b-4195a1d88104" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b81d40f5-96c1-489c-981e-864f0cc801c2" xlink:to="loc_dei_WrittenCommunications_2da1ce09-d23e-4f80-ba0b-4195a1d88104" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_960d8ebe-489e-45c5-8f66-61c12fc1e3a9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b81d40f5-96c1-489c-981e-864f0cc801c2" xlink:to="loc_dei_SolicitingMaterial_960d8ebe-489e-45c5-8f66-61c12fc1e3a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_b7c40f6e-f347-4cc2-9364-18dad5277aa8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b81d40f5-96c1-489c-981e-864f0cc801c2" xlink:to="loc_dei_PreCommencementTenderOffer_b7c40f6e-f347-4cc2-9364-18dad5277aa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_f2258d38-c514-4f84-85c5-c75912f41524" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b81d40f5-96c1-489c-981e-864f0cc801c2" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_f2258d38-c514-4f84-85c5-c75912f41524" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_0e55cb7c-ec50-454d-b7e0-41e2669db4a7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b81d40f5-96c1-489c-981e-864f0cc801c2" xlink:to="loc_dei_Security12bTitle_0e55cb7c-ec50-454d-b7e0-41e2669db4a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_f1f81744-a9c4-4c7f-8fdc-26709d0766ad" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b81d40f5-96c1-489c-981e-864f0cc801c2" xlink:to="loc_dei_TradingSymbol_f1f81744-a9c4-4c7f-8fdc-26709d0766ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_f63f31c9-24e8-4682-af57-16f062eea2ed" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b81d40f5-96c1-489c-981e-864f0cc801c2" xlink:to="loc_dei_SecurityExchangeName_f63f31c9-24e8-4682-af57-16f062eea2ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_dff52060-4b73-428d-b2cf-1cb30d062b03" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b81d40f5-96c1-489c-981e-864f0cc801c2" xlink:to="loc_dei_EntityEmergingGrowthCompany_dff52060-4b73-428d-b2cf-1cb30d062b03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>a0000a.jpg
<TEXT>
begin 644 a0000a.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !] *T# 2(  A$! Q$!_\0
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MNCK"I'>$M)+S[-><6UYBJ4)TTI;Q?5;?UY/4MT445ZQS!1110 4444 %%%%
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MH&DOTM(FSL ST=\EF;L"Q[FH?%FF?\+H_:%AT"4>;X?\/(MS?K_"Y4_)$?\
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M1="E"G/XDKR\Y2UD_G*[%KYT_;\_Y-KUG_K]L_\ T>M?1=?.G[?G_)M>L_\
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M;S_W&+K_ -DKZ>KY"_8(^('A?PS\!_L>L>)-(TJ\_M:Z?[/?7\4,FT[,':S
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@16D8QA%1BK)'0VV[L****H04444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140105223731552">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>May 04, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001806952<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May  04,  2023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Lyell Immunopharma, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40502<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">83-1300510<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">201 Haskins Way<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">South San Francisco<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94080<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">695-0677<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 par value per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LYEL<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>lyel-20230504_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="lyel-20230504.xsd" xlink:type="simple"/>
    <context id="i739733f8a8c845f0a2274d21b01731c9_D20230504-20230504">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
        </entity>
        <period>
            <startDate>2023-05-04</startDate>
            <endDate>2023-05-04</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="i739733f8a8c845f0a2274d21b01731c9_D20230504-20230504"
      id="id3VybDovL2RvY3MudjEvZG9jOmQzMTFlNGU3NTI4ZDQzMTU4OWZkYWQzYzk4MjUxODJjL3NlYzpkMzExZTRlNzUyOGQ0MzE1ODlmZGFkM2M5ODI1MTgyY180L2ZyYWc6ZTQ1ODljYmQzNWNiNDAwN2JjNzgyY2E0NmRjM2ZlYmEvdGFibGU6MGVkNmIxZTAzNTVjNDJjZmI0ZTg5ZmJjOWUyYjk1OWQvdGFibGVyYW5nZTowZWQ2YjFlMDM1NWM0MmNmYjRlODlmYmM5ZTJiOTU5ZF8yLTEtMS0xLTc5OTMw_1d2783b1-d1fa-4178-bb43-e4dc33ba1a47">0001806952</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="i739733f8a8c845f0a2274d21b01731c9_D20230504-20230504"
      id="id3VybDovL2RvY3MudjEvZG9jOmQzMTFlNGU3NTI4ZDQzMTU4OWZkYWQzYzk4MjUxODJjL3NlYzpkMzExZTRlNzUyOGQ0MzE1ODlmZGFkM2M5ODI1MTgyY180L2ZyYWc6ZTQ1ODljYmQzNWNiNDAwN2JjNzgyY2E0NmRjM2ZlYmEvdGFibGU6MGVkNmIxZTAzNTVjNDJjZmI0ZTg5ZmJjOWUyYjk1OWQvdGFibGVyYW5nZTowZWQ2YjFlMDM1NWM0MmNmYjRlODlmYmM5ZTJiOTU5ZF8zLTEtMS0xLTc5OTMw_7aa95bdf-357a-41ed-9ac5-b0b6b6fb5d99">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="i739733f8a8c845f0a2274d21b01731c9_D20230504-20230504"
      id="id3VybDovL2RvY3MudjEvZG9jOmQzMTFlNGU3NTI4ZDQzMTU4OWZkYWQzYzk4MjUxODJjL3NlYzpkMzExZTRlNzUyOGQ0MzE1ODlmZGFkM2M5ODI1MTgyY18xL2ZyYWc6YTQ2MGVlYmI5YjY4NGY4ODgwZDkxODZjNmYxMjI2MWIvdGV4dHJlZ2lvbjphNDYwZWViYjliNjg0Zjg4ODBkOTE4NmM2ZjEyMjYxYl8xNDQ3_b196b367-3410-4afa-920c-31e715ac8f0f">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="i739733f8a8c845f0a2274d21b01731c9_D20230504-20230504"
      id="id3VybDovL2RvY3MudjEvZG9jOmQzMTFlNGU3NTI4ZDQzMTU4OWZkYWQzYzk4MjUxODJjL3NlYzpkMzExZTRlNzUyOGQ0MzE1ODlmZGFkM2M5ODI1MTgyY18xL2ZyYWc6YTQ2MGVlYmI5YjY4NGY4ODgwZDkxODZjNmYxMjI2MWIvdGV4dHJlZ2lvbjphNDYwZWViYjliNjg0Zjg4ODBkOTE4NmM2ZjEyMjYxYl81NDk3NTU4MTUzNDE_9b27b38e-7b0e-4476-8ff6-de99988337b9">2023-05-04</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="i739733f8a8c845f0a2274d21b01731c9_D20230504-20230504"
      id="id3VybDovL2RvY3MudjEvZG9jOmQzMTFlNGU3NTI4ZDQzMTU4OWZkYWQzYzk4MjUxODJjL3NlYzpkMzExZTRlNzUyOGQ0MzE1ODlmZGFkM2M5ODI1MTgyY18xL2ZyYWc6YTQ2MGVlYmI5YjY4NGY4ODgwZDkxODZjNmYxMjI2MWIvdGV4dHJlZ2lvbjphNDYwZWViYjliNjg0Zjg4ODBkOTE4NmM2ZjEyMjYxYl8xNDQ5_16808414-3cad-4d72-b43d-bf0e7f66546a">Lyell Immunopharma, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i739733f8a8c845f0a2274d21b01731c9_D20230504-20230504"
      id="id3VybDovL2RvY3MudjEvZG9jOmQzMTFlNGU3NTI4ZDQzMTU4OWZkYWQzYzk4MjUxODJjL3NlYzpkMzExZTRlNzUyOGQ0MzE1ODlmZGFkM2M5ODI1MTgyY18xL2ZyYWc6YTQ2MGVlYmI5YjY4NGY4ODgwZDkxODZjNmYxMjI2MWIvdGFibGU6OThkZWJmM2FlOTMzNDA4MjkxOTUzNDBjYWMwMjg1MzAvdGFibGVyYW5nZTo5OGRlYmYzYWU5MzM0MDgyOTE5NTM0MGNhYzAyODUzMF8wLTAtMS0xLTc5OTMw_f5b740b9-a54c-4b88-ac6a-d716b03ef50b">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="i739733f8a8c845f0a2274d21b01731c9_D20230504-20230504"
      id="id3VybDovL2RvY3MudjEvZG9jOmQzMTFlNGU3NTI4ZDQzMTU4OWZkYWQzYzk4MjUxODJjL3NlYzpkMzExZTRlNzUyOGQ0MzE1ODlmZGFkM2M5ODI1MTgyY18xL2ZyYWc6YTQ2MGVlYmI5YjY4NGY4ODgwZDkxODZjNmYxMjI2MWIvdGFibGU6OThkZWJmM2FlOTMzNDA4MjkxOTUzNDBjYWMwMjg1MzAvdGFibGVyYW5nZTo5OGRlYmYzYWU5MzM0MDgyOTE5NTM0MGNhYzAyODUzMF8wLTItMS0xLTc5OTMw_0ec8395b-1539-49c9-9719-d7a5e32380a8">001-40502</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="i739733f8a8c845f0a2274d21b01731c9_D20230504-20230504"
      id="id3VybDovL2RvY3MudjEvZG9jOmQzMTFlNGU3NTI4ZDQzMTU4OWZkYWQzYzk4MjUxODJjL3NlYzpkMzExZTRlNzUyOGQ0MzE1ODlmZGFkM2M5ODI1MTgyY18xL2ZyYWc6YTQ2MGVlYmI5YjY4NGY4ODgwZDkxODZjNmYxMjI2MWIvdGFibGU6OThkZWJmM2FlOTMzNDA4MjkxOTUzNDBjYWMwMjg1MzAvdGFibGVyYW5nZTo5OGRlYmYzYWU5MzM0MDgyOTE5NTM0MGNhYzAyODUzMF8wLTQtMS0xLTc5OTMw_466789f5-4b1d-448e-a11e-6e1fafb8376d">83-1300510</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i739733f8a8c845f0a2274d21b01731c9_D20230504-20230504"
      id="id3VybDovL2RvY3MudjEvZG9jOmQzMTFlNGU3NTI4ZDQzMTU4OWZkYWQzYzk4MjUxODJjL3NlYzpkMzExZTRlNzUyOGQ0MzE1ODlmZGFkM2M5ODI1MTgyY18xL2ZyYWc6YTQ2MGVlYmI5YjY4NGY4ODgwZDkxODZjNmYxMjI2MWIvdGFibGU6OThkZWJmM2FlOTMzNDA4MjkxOTUzNDBjYWMwMjg1MzAvdGFibGVyYW5nZTo5OGRlYmYzYWU5MzM0MDgyOTE5NTM0MGNhYzAyODUzMF8zLTAtMS0xLTc5OTMw_b35d179e-8f6d-446c-8d21-d4141511617f">201 Haskins Way</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i739733f8a8c845f0a2274d21b01731c9_D20230504-20230504"
      id="id3VybDovL2RvY3MudjEvZG9jOmQzMTFlNGU3NTI4ZDQzMTU4OWZkYWQzYzk4MjUxODJjL3NlYzpkMzExZTRlNzUyOGQ0MzE1ODlmZGFkM2M5ODI1MTgyY18xL2ZyYWc6YTQ2MGVlYmI5YjY4NGY4ODgwZDkxODZjNmYxMjI2MWIvdGFibGU6OThkZWJmM2FlOTMzNDA4MjkxOTUzNDBjYWMwMjg1MzAvdGFibGVyYW5nZTo5OGRlYmYzYWU5MzM0MDgyOTE5NTM0MGNhYzAyODUzMF80LTAtMS0xLTc5OTMwL3RleHRyZWdpb246ZjUzMDM5ZWEwOTE1NGMwZjg5NzZmOTUzNWI0ODBlN2NfNA_abf802e4-5f7a-4d97-8fa2-36746c301339">South San Francisco</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i739733f8a8c845f0a2274d21b01731c9_D20230504-20230504"
      id="id3VybDovL2RvY3MudjEvZG9jOmQzMTFlNGU3NTI4ZDQzMTU4OWZkYWQzYzk4MjUxODJjL3NlYzpkMzExZTRlNzUyOGQ0MzE1ODlmZGFkM2M5ODI1MTgyY18xL2ZyYWc6YTQ2MGVlYmI5YjY4NGY4ODgwZDkxODZjNmYxMjI2MWIvdGFibGU6OThkZWJmM2FlOTMzNDA4MjkxOTUzNDBjYWMwMjg1MzAvdGFibGVyYW5nZTo5OGRlYmYzYWU5MzM0MDgyOTE5NTM0MGNhYzAyODUzMF80LTAtMS0xLTc5OTMwL3RleHRyZWdpb246ZjUzMDM5ZWEwOTE1NGMwZjg5NzZmOTUzNWI0ODBlN2NfOA_1c0041af-e184-45ef-9f1d-d3899ba82393">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i739733f8a8c845f0a2274d21b01731c9_D20230504-20230504"
      id="id3VybDovL2RvY3MudjEvZG9jOmQzMTFlNGU3NTI4ZDQzMTU4OWZkYWQzYzk4MjUxODJjL3NlYzpkMzExZTRlNzUyOGQ0MzE1ODlmZGFkM2M5ODI1MTgyY18xL2ZyYWc6YTQ2MGVlYmI5YjY4NGY4ODgwZDkxODZjNmYxMjI2MWIvdGFibGU6OThkZWJmM2FlOTMzNDA4MjkxOTUzNDBjYWMwMjg1MzAvdGFibGVyYW5nZTo5OGRlYmYzYWU5MzM0MDgyOTE5NTM0MGNhYzAyODUzMF80LTQtMS0xLTc5OTMw_54e6ec83-baa3-4490-bf14-d1b7bf569c23">94080</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i739733f8a8c845f0a2274d21b01731c9_D20230504-20230504"
      id="id3VybDovL2RvY3MudjEvZG9jOmQzMTFlNGU3NTI4ZDQzMTU4OWZkYWQzYzk4MjUxODJjL3NlYzpkMzExZTRlNzUyOGQ0MzE1ODlmZGFkM2M5ODI1MTgyY18xL2ZyYWc6YTQ2MGVlYmI5YjY4NGY4ODgwZDkxODZjNmYxMjI2MWIvdGV4dHJlZ2lvbjphNDYwZWViYjliNjg0Zjg4ODBkOTE4NmM2ZjEyMjYxYl8xNDUw_7ffd3a77-4bca-405b-a54d-3b48e0c9f219">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i739733f8a8c845f0a2274d21b01731c9_D20230504-20230504"
      id="id3VybDovL2RvY3MudjEvZG9jOmQzMTFlNGU3NTI4ZDQzMTU4OWZkYWQzYzk4MjUxODJjL3NlYzpkMzExZTRlNzUyOGQ0MzE1ODlmZGFkM2M5ODI1MTgyY18xL2ZyYWc6YTQ2MGVlYmI5YjY4NGY4ODgwZDkxODZjNmYxMjI2MWIvdGV4dHJlZ2lvbjphNDYwZWViYjliNjg0Zjg4ODBkOTE4NmM2ZjEyMjYxYl8xNDQ0_d6d4be8d-409d-4f53-a98f-8411443baf74">695-0677</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="i739733f8a8c845f0a2274d21b01731c9_D20230504-20230504"
      id="id3VybDovL2RvY3MudjEvZG9jOmQzMTFlNGU3NTI4ZDQzMTU4OWZkYWQzYzk4MjUxODJjL3NlYzpkMzExZTRlNzUyOGQ0MzE1ODlmZGFkM2M5ODI1MTgyY18xL2ZyYWc6YTQ2MGVlYmI5YjY4NGY4ODgwZDkxODZjNmYxMjI2MWIvdGFibGU6NGQxMjU4OTU1Y2JiNDM3ZDg1ZWU2ZDE2ZGVjOThiY2MvdGFibGVyYW5nZTo0ZDEyNTg5NTVjYmI0MzdkODVlZTZkMTZkZWM5OGJjY18wLTAtMS0xLTc5OTMw_9e28390f-decb-46f4-8936-8727ad92aace">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="i739733f8a8c845f0a2274d21b01731c9_D20230504-20230504"
      id="id3VybDovL2RvY3MudjEvZG9jOmQzMTFlNGU3NTI4ZDQzMTU4OWZkYWQzYzk4MjUxODJjL3NlYzpkMzExZTRlNzUyOGQ0MzE1ODlmZGFkM2M5ODI1MTgyY18xL2ZyYWc6YTQ2MGVlYmI5YjY4NGY4ODgwZDkxODZjNmYxMjI2MWIvdGFibGU6NGQxMjU4OTU1Y2JiNDM3ZDg1ZWU2ZDE2ZGVjOThiY2MvdGFibGVyYW5nZTo0ZDEyNTg5NTVjYmI0MzdkODVlZTZkMTZkZWM5OGJjY18yLTAtMS0xLTc5OTMw_ea56a240-bfff-4b74-88c7-d2cbeb286d98">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="i739733f8a8c845f0a2274d21b01731c9_D20230504-20230504"
      id="id3VybDovL2RvY3MudjEvZG9jOmQzMTFlNGU3NTI4ZDQzMTU4OWZkYWQzYzk4MjUxODJjL3NlYzpkMzExZTRlNzUyOGQ0MzE1ODlmZGFkM2M5ODI1MTgyY18xL2ZyYWc6YTQ2MGVlYmI5YjY4NGY4ODgwZDkxODZjNmYxMjI2MWIvdGFibGU6NGQxMjU4OTU1Y2JiNDM3ZDg1ZWU2ZDE2ZGVjOThiY2MvdGFibGVyYW5nZTo0ZDEyNTg5NTVjYmI0MzdkODVlZTZkMTZkZWM5OGJjY180LTAtMS0xLTc5OTMw_252e8134-2de0-45ca-b010-ce2ffa9e3935">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="i739733f8a8c845f0a2274d21b01731c9_D20230504-20230504"
      id="id3VybDovL2RvY3MudjEvZG9jOmQzMTFlNGU3NTI4ZDQzMTU4OWZkYWQzYzk4MjUxODJjL3NlYzpkMzExZTRlNzUyOGQ0MzE1ODlmZGFkM2M5ODI1MTgyY18xL2ZyYWc6YTQ2MGVlYmI5YjY4NGY4ODgwZDkxODZjNmYxMjI2MWIvdGFibGU6NGQxMjU4OTU1Y2JiNDM3ZDg1ZWU2ZDE2ZGVjOThiY2MvdGFibGVyYW5nZTo0ZDEyNTg5NTVjYmI0MzdkODVlZTZkMTZkZWM5OGJjY182LTAtMS0xLTc5OTMw_2a434894-8cc9-4ee3-ac7c-200e31fe1366">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="i739733f8a8c845f0a2274d21b01731c9_D20230504-20230504"
      id="id3VybDovL2RvY3MudjEvZG9jOmQzMTFlNGU3NTI4ZDQzMTU4OWZkYWQzYzk4MjUxODJjL3NlYzpkMzExZTRlNzUyOGQ0MzE1ODlmZGFkM2M5ODI1MTgyY18xL2ZyYWc6YTQ2MGVlYmI5YjY4NGY4ODgwZDkxODZjNmYxMjI2MWIvdGFibGU6YThlNTU4OGE1ZGJiNGIyYzlmMTEwNDljODMzZWZmYjUvdGFibGVyYW5nZTphOGU1NTg4YTVkYmI0YjJjOWYxMTA0OWM4MzNlZmZiNV8xLTAtMS0xLTc5OTMw_e084dac1-37fc-43ef-b791-2b1bcecd3a5c">Common Stock, $0.0001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i739733f8a8c845f0a2274d21b01731c9_D20230504-20230504"
      id="id3VybDovL2RvY3MudjEvZG9jOmQzMTFlNGU3NTI4ZDQzMTU4OWZkYWQzYzk4MjUxODJjL3NlYzpkMzExZTRlNzUyOGQ0MzE1ODlmZGFkM2M5ODI1MTgyY18xL2ZyYWc6YTQ2MGVlYmI5YjY4NGY4ODgwZDkxODZjNmYxMjI2MWIvdGFibGU6YThlNTU4OGE1ZGJiNGIyYzlmMTEwNDljODMzZWZmYjUvdGFibGVyYW5nZTphOGU1NTg4YTVkYmI0YjJjOWYxMTA0OWM4MzNlZmZiNV8xLTItMS0xLTc5OTMw_834355cc-580c-49fd-93ba-0e696572e6ae">LYEL</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i739733f8a8c845f0a2274d21b01731c9_D20230504-20230504"
      id="id3VybDovL2RvY3MudjEvZG9jOmQzMTFlNGU3NTI4ZDQzMTU4OWZkYWQzYzk4MjUxODJjL3NlYzpkMzExZTRlNzUyOGQ0MzE1ODlmZGFkM2M5ODI1MTgyY18xL2ZyYWc6YTQ2MGVlYmI5YjY4NGY4ODgwZDkxODZjNmYxMjI2MWIvdGFibGU6YThlNTU4OGE1ZGJiNGIyYzlmMTEwNDljODMzZWZmYjUvdGFibGVyYW5nZTphOGU1NTg4YTVkYmI0YjJjOWYxMTA0OWM4MzNlZmZiNV8xLTQtMS0xLTc5OTMw_72514af5-1baf-4b4a-b2a1-65536da595a9">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="i739733f8a8c845f0a2274d21b01731c9_D20230504-20230504"
      id="id3VybDovL2RvY3MudjEvZG9jOmQzMTFlNGU3NTI4ZDQzMTU4OWZkYWQzYzk4MjUxODJjL3NlYzpkMzExZTRlNzUyOGQ0MzE1ODlmZGFkM2M5ODI1MTgyY18xL2ZyYWc6YTQ2MGVlYmI5YjY4NGY4ODgwZDkxODZjNmYxMjI2MWIvdGV4dHJlZ2lvbjphNDYwZWViYjliNjg0Zjg4ODBkOTE4NmM2ZjEyMjYxYl8xNDQ1_af72d6f6-909a-45f3-83a4-8420385e49fb">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M49NA%W@?-Y[$:FW=#7\TR-B*S[G]-9MI:/FE2BQ2+HU0DFB^''KCX.HZ[+B
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M]QA)Y?@A[LX?0T:F[]&:R14_NG%K$'H<SV_&OV!,E=6')UG]-.5ZY4;I$RA
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MJ#(9BBJ6<%H@XLD@;6E6?;!/3K3G>1<W]T6NS>,)KM\,<'AT_@%02P,$%
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M?^:+X3]>?P%02P$"% ,4    " !P@:16!T%-8H$   "Q    $
M    @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( '"!I%;0>;DQ
M[@   "L"   1              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+
M 0(4 Q0    ( '"!I%:97)PC$ 8  )PG   3              "  <P!  !X
M;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ <(&D5IHN[:-.!   AQ
M !@              ("!#0@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+
M 0(4 Q0    ( '"!I%:?H!OPL0(  .(,   -              "  9$,  !X
M;"]S='EL97,N>&UL4$L! A0#%     @ <(&D5I>*NQS     $P(   L
M         ( !;0\  %]R96QS+RYR96QS4$L! A0#%     @ <(&D5JK$(A8S
M 0  (@(   \              ( !5A   'AL+W=O<FMB;V]K+GAM;%!+ 0(4
M Q0    ( '"!I%8D'INBK0   /@!   :              "  ;81  !X;"]?
M<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( '"!I%9ED'F2&0$
M ,\#   3              "  9L2  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%
3!@     )  D /@(  .43      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="lyel-20230504.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lyell.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="lyel-20230504.htm">lyel-20230504.htm</File>
    <File>lyel-20230504.xsd</File>
    <File>lyel-20230504_lab.xml</File>
    <File>lyel-20230504_pre.xml</File>
    <File>lyel-20230504x8kexx991.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "lyel-20230504.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2022": 22
   },
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "lyel-20230504.htm"
     ]
    },
    "labelLink": {
     "local": [
      "lyel-20230504_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "lyel-20230504_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "lyel-20230504.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 23,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 22,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "lyel",
   "nsuri": "http://www.lyell.com/20230504",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyel-20230504.htm",
      "contextRef": "i739733f8a8c845f0a2274d21b01731c9_D20230504-20230504",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentPeriodEndDate",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.lyell.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyel-20230504.htm",
      "contextRef": "i739733f8a8c845f0a2274d21b01731c9_D20230504-20230504",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentPeriodEndDate",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lyell.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lyell.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lyell.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lyell.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lyell.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lyell.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lyell.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lyell.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lyell.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lyell.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lyell.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lyell.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lyell.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lyell.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lyell.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lyell.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lyell.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lyell.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lyell.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lyell.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lyell.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lyell.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001628280-23-015733-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-23-015733-xbrl.zip
M4$L#!!0    ( '"!I%8]^<F88Q0  +:,   1    ;'EE;"TR,#(S,#4P-"YH
M=&WM7>MWVKBV_W[^"EWFWG/2M2*P_#9I<U8FD)1., TA9>!+EFS)8&(P8YL
M^>OOEFV2D"=IFP3:S%HS$Z/7EK3UVP]M21__.QL&Z()'L1^./A5(42J@_^Y^
M_!^,__ZS>80JH3L9\E&"]B-.$\[0U$_ZJ,UX?(Z\*!RB=AB=^Q<4X[3,?CB>
M1WZOGR!9DI5;B5&9,<NDNJ=@W:(R5A5.,'5T$TLNDSU5YR95E.U>F6B6R2Q*
ML:EK!*NZR;#EZ1J65,O1J>%JGJQMLS)3".$J-S399*I"--/R&&6*:YFR1DS9
M%<WV$^@=]' 4EQGW/Q7Z23(NETHS)PJ*,7>+O?"B! DE(%<NY!EG@3\ZO\HZ
MG4Z+4Z481KT2L2RKE*8NLOJSI7QIM2*G+!&EY(\@*Q?#>%5S[-]7KRQ)I/1W
M_>C$[?,AQ?XH3NC(Y=>-)/>W<MU *8GH*/;":$@3F$?1'0E+,B:+3CW<'3%"
M-UK","I+F1>C]%AC!.;&Q I9U'-G &\,C*241+)#XZL.BE3_D?Q+ U(.Z*CW
MJ<!'^/2D !/,*=O]..0)1:(\YO],_(M/A?UPE #;XM9\#,7<[.M3(>&SI)3V
MN+3[KW_]ZV/B)P'?#>8\P()A)4U2/Y:R'S^6LJJ=D,UW/S+_ L7)/."?"LR/
MQP&=ET?AB ,!_JPL,O(H^]-GC(_2/R'=AK43^6[6_BQI<N]3P3<4RU 4SZ2F
M:ZJ:)U%9-E0F$T<BAD)<ZZRR(.6*I@(:T:%HFOOEZ@CHF^]#=R(:U$:,S_[B
M\P+R&53-E&]SIQ)>',G-BXY2G[!!]:)[: T:P^/+>NL@L ]/%;M54[L5\7VJ
M-MK=\T[[^+)S>:[6!Z>S1N7+X$BQ@\[E^+Q^69UU6\W OCR=-PZ/)?@FC4HP
M[!X>G-?ENM:HU$B]U9MWB"D=R=UYI^WJW=:QR#/H0'MVV_;MRM[4EK\,[$O(
M)U<E>]@<U.5NT!E6+]CA@>\<GNKUPV_G]K &;>U=VJUO QMHZ YK4K?5T[K#
M+X-&^W3>&9R31OLX+_,-VM)&W58X[;:/Y<[@(*A7ZL1NUZ7ZT!YV!LU T-D9
MUK5NZXO?:)UJW0-S?M2J)O43:7;4<K5&JSX](TPV3,4AF!&/8I48)G8<5<%<
M9:ZB.)10U2CL2K V34FW-/EC:6E27W*.]P!RF8#=@X#VWN?VJ;F]O#.W!J66
MYC /*YHAYI:#!*&NAAW)T1W=<S1F685=CP8QOS.MI>5E''&/1QS0)[X'?022
ME>,4MF'B42H;R@E@SJ="[ _'@8"L]+=^)/AB"6B*LYA!%:7E.K+VKQO-:8C#
M291^I5A9SIDMXXSO8;9%13Q%D\67S\2WY_,(I03Q>R7!?NVOY75QN_#NXJ?E
MVL<POB%;? &D1TD%=(I=0126A'A?E+M.NR*3/9!UD;+X7C126AJHQ:A>#6/I
M!FR7 -PSA,\7VN-JQ1DIW"R32X6A/\)]+E2?LJJ-DYVISY)^F4C2_Q72?+L?
MXS$%CG*B$I3._LXJN5L5C7I06Q*.R\HX@>()=0*^2'7""*C&;A@$=!SS\N*/
MG85<R@0U3@OMY'4Y89*$P[(@#%2]Q'=I@&G@]T9E,3IY\C7-12FC.X'12=BB
MY3RYF":5$G8WS3*+EO1PLE0D5VFEM.YHD2$?NKR_#- T$&/TJ: 4;G4\[PKD
M1"R<B('Y ZC=&5/&_%&O+"&2UG'=2"D=B2?'>2<=B6Q07&!<'A6R.5MD!Y+"
MJ"P:$^UYP%C8HT,_F)?_T_*'  \VGZ)F.*2C_VS'H""!)A7Y7I8Q]B]YF9C0
M2OHYS7IK0#WI7.6])[(8NU.[UJI6T$EKKU4]66:5]2?^I+I_VJRU:M43M&=7
M4/7O_<][]F$5[3?J]=K)2:UAKT^/Y)5ZU-X[^5RS#UL->QM5BOM%L&PTU5J?
M7DBW>J'>VXNS9_VS/KU;C>L.&LTZ>D%];&$%9];$6ZICLX4ZUFD=RZ!>@;I5
MTSJ#CFH?=M1&I3?M5LZA[NX E*59?5"3Z^T:J%;?5/;Y2]"5@PMG,.[;E0ZH
M5]_\SB#P[4%/Z@YZ4/;/\T:KJMI#4.(&U7E]T)EU G-F5XZ5,X=8NJ/H!E94
M(F&5@KYLR9(+%A\WB$9=TY.\PJZ)_[JK3*T+(_W:RV0U* -H;E;M%FI6OS::
MK4VC_NLDBB=TE* D1"?<%:X'1!041HAH6^P#"CV4]+E(FD1^XD/#U9G;!W6=
MHSTW$<G$4M1-Z[50;@7M33X.HP1M+;XY!?66QPGB%\(]%Z7)G'THOP8.?DV5
M[&JF>A=0Y@J"ZF=)F<$O> AM]D4QS.@<SX%6S$>_%W 2NW(._3A5H0^7=J5Z
M9CFRX2@FQX8C<:RJAHY-S],QXY9EF::B& Z8I'4Z__<?1)=VU.W4A?H.J&_2
M.UE=:7&^N)NOR7M^+-RMB0TIO]<*$JJ'=D9T4S)5HF+%I0RKS)"QHRH,.Y[$
M#4_7-56GA=VC.0\"5!L.)Z-PW*< 1]NH-G*+:[M\C)7X:ZLZHR"Z!%=D,F#!
M#8C&Z&3,7>%N8<@?H5H2HWWH.)#Z86TZ^988L4EN$]DJRI*RDMOD>6FJI']7
MR<>(58RB9'XO0:]-;#JRZG,<4@]YGQ;^)7D\$QZFNXOG-H=DS/'B2^H.<$BO
M(I@ 7,,(5,YT!_ D :5O/YR,DFB^'[)EC5!L* J';L+'47@AZME053#;TFBT
M^N?=]A<050=!HU4'U6X/:('\J9KWYZ#3KD_K@QZI7^[=WM+0&H=-:*MSV6F?
M:O7+NE2O].8@^#2[!7\?VOW.Y=Z\43F]K!^8TZ/6WO*6AJ<YABHY%J::ZF+5
M,4U,79UB9A#=D13N:9(#Y@(/Z)1&]^QJY*B9+X-'.'S)@_J^&%98# =^P*%V
M!R3H.V,_S=BU9<:6N&LJEN9@HBD65BW7PI9!+&!LJG%%5DR)FF*_B6 5AO_N
M-NP[9[\<9[?HK)9OZ[DIU+^S^<IL?KS,YJJN&Z;E:0#=! P9U>28$L*QSHE'
M/<=4#)T5=DT%$T62-"(]RN<_6UD!I?G5+9R4@[=2W4$X\1I)GT?HRR3R8^9G
MWKUTLQ3LGB5EX\,;+_BW&ZK]<#CT8Q&GAX3$0=E:_'W'H]8\0=7A. CGP#@I
MKRQC%;+#XH?[ELVM36>B/K+K_!U#MUY9W^V:YPB\/<8B'L?Y_XZ  /(N[)X2
M=I=WC!5'T1@Q+(Y-3Q?"3G>Q"5.!F4I4HA&B$\,K[,H209]I?.Z/8M2F\]?1
M[-9ZR07<N^-JNEIP-WQ=K^^Z>]OUN ]_-J)6.'UW'3RY&J7;J_%(:0;\<W/>
M;;.Q(ZMZ=P#Y*G6MVZY.H0YB']:GW4%/LR^[PY26=DUJ5/X,;-GV[+TSZGBF
M)',5:YZ(I626 :N:REC1#5C7BD04Q2KLGH23I(].@ 4/(CIR_=@-;Z_G[9?<
MFEQBEU2I;$1?H_#"3^/&W_U1Z\14C;TSXDJ22JB'.3%5K&K<PY8'=A%33,MR
MJ"DKEE+8W0>(@ZD;^?3QC9SU@/UW!6OU%?HUA"48=/UQYB]^7WY/+K];[@1-
MY;IPG&&'4@4T+$O"CD=4S(AC.)ZF6ZX,"\A2)?-U/0DOP[TK6H0Y<XF]TJ\1
M(+\_I@&JSK@[2?P+CAH>F(8\?B&+^9>$C14''A8R$BOY'G-[U?#KO,-8J,!B
M3T^[\5N4M97]N :Z;[IM?;T;_^\_3)D8.S%J\8"/^^%HX9M)@Q""B>@#VHLX
M3<>HO!BCM]AK1Z_3^*N'RP@#08SPQHJ3'PF3.9V>&9['%&H86'5<*C9*'+%/
MR+#BJ":77,N3"2CINO:@,'AGQI_'C$<AP/)7@0,;O%WR0W%;TAG3F>IPDP$O
M6O ?3U,PM4P/FRHAJJHXU#-48$A+PY)N&&L;I[4B,VT=@(')(V2GD5H1RC]S
M?60;^9Z(SAKU.$,GPB)%1S1.\IC>-8[7NK^S=IB@O?$X .4#)/OZ4O^ZT69O
MT9?]/G?/TZAW.AY'X3CRQ6::$\Z0PX-P*MA.) IN1";^"WE^(%01/T:^.!#/
M@!V3$,7^<!(D=,3#21S,44P3/_;F:<F\0.C O&5[*GF4?70=BCB!>B)$1_-%
MFA<&T+@H)SPLOMBPBLOH5XS;*UK6:J<=GW6(4BV:Y%F'*'^2H_E9.WEMJ%A4
M'G\W!Q/Y9:5P._(38'*Q:SH9Y5N"\?)A!<^?<8;38^ ;*:,S'X1]> R_ 2VM
M4]*1O_AVI:YT*SW2;9_*W4I5[AY^&S1:?;\CUV_[("1(G]NMGB9.YT.;0",[
M;U2^!=U6][P._W;;0.?AEP'0>#<DS>*RJ5B2AQEW':SJGHI-2]&Q:<@&999,
MJ<L+NW?\P,\PO[]CB^1MD#AG-NC+36Y#XQMGEIH30#55UG+ O'5621Q1VB(&
MVC]H(N#E(F3\<(^3\_G'IM=K,^L7PYB3$+0@F,!1KPZ2%\1O\ XPWPTP\SL
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MM2(JJ$U/6YS,ATX8;+U4/,UF#(B=W\V0L@=?B!V VVG?AU^N,?DY45<YQ H
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M7G8_UNUS'D(@;_P1C]=;#K=BS U9(RKU-$P<*K9?5(H=F1*L:YJB,ZI9&K5
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MA&Y?TKR-'KI_%FT),!,JEBSMY*(Z_2(['T!?C"> A11@41Q:!+;F%("8CD:
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MN*:GP21G#&!3<V8#]_+S_;VXUK^*^J1_J2DC"B:4"@#C)*@Z_A3P!/M !4'
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MC[+>5 S:@$'F,(P0M[)#/66D%NZV-*(@)P%H@'UXE,1=Q4\Z8I0\A/=,.NT
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MP.82/U?M+);<(<TY^ZWLBE)!\;I0C*?%TE3^DJ8-MH(3DH<Y+/Z''TBHSA;
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M-"YH=&U02P$"% ,4    " !P@:16[S@X>F8"  !E!P  $0
M@ &2%   ;'EE;"TR,#(S,#4P-"YX<V102P$"% ,4    " !P@:16 _&P=T *
M   870  %0              @ $G%P  ;'EE;"TR,#(S,#4P-%]L86(N>&UL
M4$L! A0#%     @ <(&D5N7+S.&G!@  UC   !4              ( !FB$
M &QY96PM,C R,S U,#1?<')E+GAM;%!+ 0(4 Q0    ( '"!I%:N?J_EAA\
M ,A1 0 :              "  70H  !L>65L+3(P,C,P-3 T>#AK97AX.3DQ
:+FAT;5!+!08     !0 % $P!   R2      !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
